Endpoint choice for inclusion body myositis: a step too far?

Affiliations

¹ Department of Neurology, Muscle Immunobiology Group, Neuromuscular Center, University Medical Center Göttingen, 37075 Göttingen, Germany. Electronic address: j.schmidt@gmx.org.

Comment

Jens Schmidt. Lancet Neurol. 2019 Sep.

. 2019 Sep;18(9):807-808.

doi: 10.1016/S1474-4422(19)30279-0.

¹ Department of Neurology, Muscle Immunobiology Group, Neuromuscular Center, University Medical Center Göttingen, 37075 Göttingen, Germany. Electronic address: j.schmidt@gmx.org.

No abstract available

Comment on

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.
Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Katsuno M, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Auberson LZ, Wu M, de Vera A, Papanicolaou DA, Amato AA; RESILIENT Study Group. Hanna MG, et al. Lancet Neurol. 2019 Sep;18(9):834-844. doi: 10.1016/S1474-4422(19)30200-5. Lancet Neurol. 2019. PMID: 31397289 Clinical Trial.